CN Patent

CN105813635A — 药物剂型

Assigned to Novartis AG · Expires 2016-07-27 · 10y expired

What this patent protects

本发明关于固体药物剂型，包含原料药3(2,6二氯3,5二甲氧基苯基)1{6[4(4乙基哌嗪1基)苯胺基]嘧啶4基}1甲基脲或其任何药学上可接受的盐。本发明进一步关于制造这些固体药物剂型的方法。

USPTO Abstract

本发明关于固体药物剂型，包含原料药3(2,6二氯3,5二甲氧基苯基)1{6[4(4乙基哌嗪1基)苯胺基]嘧啶4基}1甲基脲或其任何药学上可接受的盐。本发明进一步关于制造这些固体药物剂型的方法。

Drugs covered by this patent

infigratinib-phosphate (INFIGRATINIB PHOSPHATE)

Patent Metadata

Patent number: CN105813635A
Jurisdiction: CN
Classification: —
Expires: 2016-07-27
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.